Vasculitis & polymyalgia rheumatica
Trans-omics landscape of systemic vasculitis identified matrix metalloproteinase 12 as a novel signature molecule
Authors' conclusion
MMP12 is a disease-specific molecule that is associated with macrophage maturation and the formation of multinucleated giant cells and reflects disease activity independently of the IL-6 pathway in systemic vasculitis.
Study context
- Population
- Patients with newly diagnosed or relapsed rheumatic and musculoskeletal diseases, June 2013 to September 2022
Methodological detailstrans-omics analysis, serum proteome analysis, whole-blood RNA sequencing, immunohistochemical staining, spatial transcriptome analysis
- Trans-omics analysis
- Serum proteome analysis
- Whole-blood RNA sequencing
- Immunohistochemical staining
- Spatial transcriptome analysis
Main finding
As reported in the abstract
- Serum proteome and RNA sequencing identified MMP12 as a significant molecule for systemic vasculitis
- MMP12 distinguished vasculitis from other rheumatic and musculoskeletal diseases
- MMP12 reflected disease activity along with longitudinal change
- MMP12 predicted relapse in patients with LVV
- MMP12 could detect insidious disease activity even under IL-6 inhibition
- MMP12 specifically expressed in tissue-infiltrating CD206-positive macrophages (immunohistochemistry)
- MMP12-positive macrophages: characteristic phenotype associated with macrophage maturation and multinucleated giant cell formation (spatial transcriptomics)
Original publication
Trans-omics landscape of systemic vasculitis identified matrix metalloproteinase 12 as a novel signature molecule. Rheumatology (Oxford). Published 26 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →